Clinical trialNCT06096909RecruitingPhase 4Interventional

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

SponsorChina National Center for Cardiovascular DiseasesEnrollment3,684Acute Coronary SyndromeLipid Lowering, Vascular InflammationNon ST Segment Elevation Acute Coronary Syndrome

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Na-Qiong Wu, Doctor
Chinese Academy of Medical Sciences, Fuwai Hospital
Principal Investigator
clinicaltrials.gov ↗
Yong-Jian Wu, Doctor
Chinese Academy of Medical Sciences, Fuwai Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Fuwai Hospital
Beijing, Beijing Municipality, China
Na-Qiong Wu, Doctor
Recruiting
Tangshan Central Hospital
Tangshan, Hebei, China
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cholesterol Absorption InhibitorStatinTafolecimab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Nov 2023
Primary completion: 1 Mar 2028
Completion: 1 Jun 2028
Last update posted: 27 Oct 2026
Registered enrollment: 3,684
Registry id: NCT06096909

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.